Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.175
-0.035 (-1.09%)
At close: Sep 10, 2025, 4:00 PM
3.180
+0.005 (0.16%)
After-hours: Sep 10, 2025, 4:00 PM EDT
Rocket Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts that cover Rocket Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $12.96, which forecasts a 308.19% increase in the stock price over the next year. The lowest target is $2.50 and the highest is $44.
Price Target: $12.96 (+308.19%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Rocket Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 4 | 4 | 4 |
| Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Hold | 1 | 4 | 4 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 12 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $4 → $10 | Hold → Strong Buy | Upgrades | $4 → $10 | +214.96% | Aug 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +246.46% | Aug 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +246.46% | Aug 11, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $10 → $8 | Buy | Maintains | $10 → $8 | +151.97% | Aug 8, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 → $10 | Strong Buy | Maintains | $11 → $10 | +214.96% | Jul 25, 2025 |
Financial Forecast
Revenue This Year
13.72M
Revenue Next Year
28.61M
from 13.72M
Increased by 108.43%
EPS This Year
-2.13
from -2.73
EPS Next Year
-1.63
from -2.13
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 150.2M | 150.2M | |||
| Avg | 13.7M | 28.6M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 994.1% | |||
| Avg | - | 108.4% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.90 | -1.13 | |||
| Avg | -2.13 | -1.63 | |||
| Low | -2.31 | -2.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.